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Purpose: Autosomal dominant optic atrophy (ADOA, OMIM 165500), an inherited optic neuropathy that leads to retinal
ganglion cell degeneration and reduced visual acuity during the early decades of life, is mainly associated with mutations
in the OPA1 gene. Here we report a novel ADOA phenotype associated with a new pathogenic OPA1 gene mutation.
Methods: The patient, a 62-year-old woman, was referred for acute, painless, and severe visual loss in her right eye. Acute
visual loss in her left eye occurred a year after initial presentation. MRI confirmed the diagnosis of isolated atrophic
bilateral optic neuropathy. We performed DNA sequencing of the entire coding sequence and the exon/intron junctions
of the OPA1 gene, and we searched for the mitochondrial DNA mutations responsible for Leber hereditary optic atrophy
by  sequencing  entirely  mitochondrial  DNA.  Mitochondrial  respiratory  chain  complex  activity  and  mitochondrial
morphology were investigated in skin fibroblasts from the patient and controls.
Results: We identified a novel heterozygous missense mutation (c.2794C>T) in exon 27 of the OPA1 gene, resulting in
an amino acid change (p.R932C) in the protein. This mutation, which affects a highly conserved amino acids, has not
been previously reported, and was absent in 400 control chromosomes. Mitochondrial DNA sequence analysis did not
reveal any mutation associated with Leber hereditary optic neuropathy or any pathogenic mutations. The investigation of
skin fibroblasts from the patient revealed a coupling defect of oxidative phosphorylation and a larger proportion of short
mitochondria than in controls.
Conclusions: The presence of an OPA1 mutation indicates that this sporadic, late-onset acute case of optic neuropathy
is related to ADOA and to a mitochondrial energetic defect. This suggests that the mutational screening of the OPA1 gene
would be justified in atypical cases of optic nerve atrophy with no evident cause.
Autosomal  dominant  optic  atrophy  (ADOA,  OMIM
165500) is a hereditary disorder characterized by progressive
loss of visual acuity in the early decades of life, color vision
deficits, optic nerve pallor, and central or centrocecal visual
field  scotoma  [1,2].  ADOA  occurs  with  an  estimated
prevalence of 1:50,000 in most populations [3], and 1:10,000
in Denmark [4]. This hereditary optic neuropathy leads to
phenotypic heterogeneity, even among members of a given
family [5]. Histopathological studies indicate that ADOA is
caused by the degeneration of retinal ganglion cells followed
by the ascending atrophy of the optic nerve [6].
In  2000,  two  research  groups  identified  OPA1  gene
mutations on chromosome 3q28 as causing ADOA [7,8]. The
OPA1  gene  encodes  a  dynamin-related  guanosine
triphosphatase (GTPase) and is composed of 31 exons [9]. As
of January 2009, 204 OPA1 pathogenic mutations have been
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reported, mainly in the GTPase and the C-terminal domains
of the protein (eOPA1) [10]. The OPA1 protein is localized
to the mitochondrial intermembrane space, where it facilitates
fusion between mitochondria [11]. The protein is involved in
several mitochondrial functions, such as the maintenance of
the integrity of the cristae formed by the mitochondrial inner
membrane [12], the regulation of cytochrome c release during
apoptosis [13], and the maintenance of mitochondrial DNA
[14,15].
Studies of patients carrying pathogenic OPA1 mutations
have revealed the great diversity of clinical presentations of
ADOA by the description of congenital forms of the disease
[16], of forms with spontaneous visual recovery [17], and
forms associated with extraocular symptoms such as deafness
[18],  polyneuropathy  [19],  chronic  progressive
ophthalmoplegia [20], myopathy, and encephalopathy [14,
15]. An energy impairment has been found to be associated
with  the  disease  in  vivo  [21]  as  well  as  in  the  patient's
fibroblasts [22]. In addition to this energy impairment, it has
been  shown  that  the  mitochondrial  network  of  mutated
fibroblasts was frequently fragmented and that some OPA1
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598mutations  were  associated  to  increased  susceptibility  to
apoptosis  [23].  Lastly,  patients  with  severe  ADOA  with
extraocular  symptom  were  found  to  harbor  multiple
mitochondrial DNA deletions [14,15], reinforcing the strong
links existing between mitochondrial structure maintenance
and mitochondrial energetic metabolism in neurodegenerative
diseases.
The aim of the present report is to show that a clinical
phenotype similar to that of late-onset Leber hereditary optic
neuropathy may be linked to an OPA1 mutation. This report,
together with other recent studies, reveals the unexpected
clinical heterogeneity of ADOA caused by OPA1 mutations.
METHODS
Patient history: A 62-year-old Caucasian woman consulted
for blurred vision. On examination, she was found to have a
central scotoma in the right eye; visual failure occurred rapidly
a few days later. She denied having had any previous ocular
symptoms,  ocular  pain,  or  systemic  symptoms  such  as
headache, muscular pain, or jaw claudication. An ophthalmic
examination documented a right optic disc edema without
peripapillary hemorrhage. No morphological abnormalities in
optic disc cupping or loss of the neuroretinal rim were found
in either eye. The visual acuity in the right eye, which had a
large central scotoma, fell to 20/400, but remained at 20/20 in
the  left  eye.  The  intraocular  pressure  in  each  eye  was
15 mmHg.
The  patient  had  no  known  vascular  risk  factors.  She
showed no signs of hypertension, diabetes, or hyperlipidemia,
and  did  not  indulge  in  alcohol  or  tobacco.  The
electrocardiogram  was  normal,  without  any  signs  of
dysrythmia. The carotid and the transcranial Doppler scans
showed  no  prominent  stenosis  or  occlusion  of  the  major
intracranial  large  arteries.  The  general  and  neurologic
examinations  were  normal.  Brain  MRI  was  normal.
Laboratory investigations were done to exclude other causes
of  arteritis,  such  as  syphilis,  hepatitis,  Lyme  disease,  or
systemic  lupus  erythromatosis.  The  erythrocyte
sedimentation rate and the C-reactive protein level were not
elevated.  A  temporal  artery  biopsy,  done  to  check  for
inflammatory arterial cells, was normal. As the patient was
suspected of having giant-cell arteritis and arteritic anterior
ischemic optic neuropathy, she was treated with 500 mg I.V.
methylprednisolone  for  three  days,  while  awaiting  biopsy
results, to prevent vision loss from progressing to the other
eye. Visual acuity remained 20/400 in the right eye, with
resolution of the disc edema.
Nine months after the loss of vision in the right eye, vision
in the left eye became blurred and worsened to 20/250 over
the following week. On ophthalmoscopic examination, the
left optic disc showed edema without splinter hemorrhages at
the disc margin. The swelling of the optic disc gradually
subsided and turned pale. The same clinical, biologic, and
radiological  investigations  as  before  showed  no
abnormalities.  Brain  and  orbital  MRI  was  normal.  Our
hypothesis was that the patient had an acute anterior ischemic
optic  neuropathy,  caused  either  by  an  inflammatory
involvement of the optic nerve or by an ischemic sequela to
vasculitis. Since there may have been some overlap between
the two conditions, the patient was treated with intravenous
methylprednisolone  to  try  to  improve  her  vision.
Nevertheless, the visual acuity remained at 20/250 in the left
eye, with resolution of the disc edema.
At the last examination six months later, the patient, still
amaurotic, was given a poor prognosis for further recovery of
the visual defects. Fundus examination revealed severe optic
disc atrophy in both eyes (Figure 1). The clinical examination
and the MRI confirmed the diagnosis of isolated bilateral optic
neuropathy. We searched for a genetic etiology. The patient’s
parents were dead; she had no brothers or sisters; but she had
a 28-year-old son who had no ophthalmic problems.
OPA1 gene analysis: Blood samples were taken from the
patient after obtaining informed consent. Genomic DNA was
extracted from blood samples using the BioRobot EZ1 and the
EZ1 DNA Blood kit (Qiagen, Courtaboeuf, France). Next, 30
primer pairs (Appendix 1) were used to amplify the 30 OPA1
coding  exons,  including  exon-intron  junctions.  PCR
amplifications of the DNA were conducted under standard
protocols. The purified PCR products were sequenced using
a  Ceq2000  DNA  sequencer  (CEQ  DTCS-Quick  Start  kit;
Beckman  Coulter,  Fullerton,  CA).  The  OPA1  mutation  is
described according to the OPA1 transcript variant 1 (RefSeq:
NM_015560).
Mitochondrial DNA analysis: To exclude the presence of any
rare mitochondrial DNA mutation, we sequenced entirely the
mitochondrial genome. The mtDNA was PCR amplified in
eight fragments using the protocol 96 °C for 10 min, followed
by 30 cycles of 96 °C for 45 s, 58 °C for 30 s, 72 °C for 3 min,
and a last extension at 72 °C for 10 min (Appendix 2). PCR
products were purified and sequenced as described in the
previous section.
Skin  fibroblasts:  The  research  followed  the  tenets  of  the
Declaration of Helsinki. Fibroblast cells were obtained from
skin biopsies taken after obtaining written consent from the
patient, as described elsewhere [24]. Fibroblasts, obtained by
explants from skin punch biopsy, were maintained in DMEM
(Invitrogen, Carlsbad, CA) with 10% bovine calf serum at
37 °C in a humidified atmosphere with 5% CO2. All fibroblast
cultures  were  mycoplasma-free,  as  shown  by  the  DAPI/
Hoechst  in  situ  coloration  and  by  PCR  (Venor®Gem,
BioValley, Marne-la-Vallée, France). All experiments were
performed on cells with similar passage numbers, ranging
from 5 to 15, so as to avoid artifacts due to senescence, known
to occur at passage numbers greater than 30.
Efficiency of mitochondrial ATP production in permeabilized
cells: The rate of mitochondrial ATP synthesis and the ATP/
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599O ratio were determined in cells permeabilized by exposure
to digitonin, as described below [24]. Cells were resuspended
in the respiratory buffer, which contained 10 mM KH2PO4,
300 mM mannitol, 10 mM KCl, and 5 mM MgCl2, pH 7.4.
This buffer was supplemented with 2 mM iodoacetate and
2 mM EDTA so as to prevent glycolytic ATP synthesis and
ATP hydrolysis by cellular ATPases. The respiratory rates
(O2/min/mg of proteins) of 3–5x106 cells were recorded at
37 °C in 2 ml glass chambers using a two-channel, high-
resolution  Oxygraph  respirometer  (Oroboros,  Innsbruck,
Austria). ATP synthesis was started by addition of 5 mM
malate, 5 mM pyruvate, and 10 mM succinate, followed by
addition of 1.5 mM ADP. Five aliquots were sampled each
minute during mitochondrial ATP synthesis, quenched with
an equal volume of 1%(W/V) TCA solution and neutralized
by adding a 25 mM HEPES, 2 mM EDTA, pH 7.75 buffer.
Three aliquots were also sampled after addition of 8 µg/ml
oligomycine (an ATP synthase inhibitor) to check for residual
nonmitochondrial ATP synthesis. The ATP synthesized in situ
was  measured  using  the  Enliten  ATP  assay  (Promega,
Madison,  WI).  Luminescence  was  measured  on  a
multidetection reader for microplates Xenius XML (SAFAS,
Monaco,  Monaco)  using  a  10-s  integration  period.
Standardization was performed with known quantities of ATP
measured  under  the  same  conditions.  Coupling  efficiency
(ATP/oxygen [ATP/O]) was measured by polarography as the
number of nanomoles of ATP produced from ADP+Pi per
nanomole of oxygen consumed by permeabilized cells. The
efficiency of the respiratory chain was tested using malate,
pyruvate, and succinate as substrates.
A  Beckman  DU  640  spectrophotometer  (Beckman
Coulter, Fullerton, CA) was used to measure the activity of
the  mitochondrial  respiratory  chain  complexes  on  cell
homogenates at 37 °C in a cell buffer that contained 250 mM
saccharose,  20  mM  tris[hydroxymethyl]aminomethane,
2  mM  EGTA,  and  1  mg/ml  BSA,  pH  7.2.  Complex  IV
(cytochrome c oxidase, COX), complex V (F1-ATPase), and
citrate synthase activities were recorded following Rustin et
al. [25]. Complex IV activity was measured in a 50 mM
KH2PO4 buffer, using 15 µM reduced cytochrome c on 105
cells permeabilized by 2.5 mM β-D-dodecylmaltoside. To
measure the activity of complex V, we first disrupted cells by
freezing  in  liquid  nitrogen,  followed  by  rapid  thawing  at
37 °C. The cells were then centrifuged for 2 min at 800× g,
resuspended  in  cell  buffer  (250  µl/106  cells).  This  was
followed by a sonication step (6×5 s with an MSE sonicator).
Complex V activity was immediately assayed on this cell
lysate  (0.5×106  cells)  in  a  Tris/KCl  buffer,  composed  of
50  mM  Tris  and  10  mM  KCl,  and  containing  2  mM
Phosphoenolpyruvate (PEP), 0.5 mM ATP, 5 mM MgCl2,
1.5  µM  FCCP,  2.5  µg/µl  antimycin  A,  0.1  U  lactate
dehydrogenase,  and  0.1  U  pyruvate  kinase  (Roche
Diagnostics, Meylan, France), 5 mg/ml BSA, pH 8. After
incubation  for  3  min,  the  reaction  was  started  by  adding
0.1 mM NADH and the rate of disappearance of NADH was
monitored at 340 nm. In addition, 10 µM oligomycin was
added  to  determine  the  background  rate  (nonspecific  for
complex V activity). Citrate synthase was assayed by standard
procedures,  using  0.15  mM  5–5-dithiobis(2-nitrobenzoic
acid) (DTNB), 0.5 mM oxaloacetate, 0.3 mM acetyl-CoA, and
0.1% (V/V) Triton X-100. Specific enzymatic activities were
expressed in mIU (e.g., nanomoles of cytochrome c, NADH
or DTNB/min/mg protein, respectively). Enzymatic activities
of complexes IV, V and citrate synthase are listed in Table 1.
Figure 1. Fundus examination. The first
image represents the patient's right eye
fundus  examination  and  we  observe
optic disk atrophy (arrow). The second
image  represents  left  eye  fundus
examination, we also observe optic disk
atrophy.
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600Mitochondrial fluorescence imaging: Cells cultured in a two-
well chamber slide (Labtek, Nunc International, Naperville,
IL) were incubated with 100 nM Mitotracker® to label the
mitochondrial  network  (Molecular  Probes,  Carlsbad,  CA)
according to manufacturer’s instructions. Z-Stack fluorescent
images  were  acquired  with  a  Leica  (DMI6000B;
Microsystems  GmbH,  Wetzlar,  Germany)  and  a  Roper
CoolSnap  HQ2  camera.  MetaMorph  software  (Molecular
Devices,  Sunnyvale,  CA)  was  used  to  analyze  images.
Mitochondrial  length  and  number  were  determined  using
integrated  morphometric  analysis  of  the  regions  created
around  mitochondria  after  deconvolution  (Metamorph®,
Molecular Devices), as described above by Cassereau et al.
[26]. Around 50 deconvolved images were used to quantify
the  mitochondrial  length.  Measurements  of  mitochondria
length distribution were divided into four groups: <1 µm, 1 to
5 µm, 5 to 10 µm, and >10 µm.
Expression of OPA1 protein: Pellets of 5×106 fibroblasts from
the patient and controls were stored at −80 °C until used for
western blot analysis. Next, 40 µg protein were solubilized in
Laemmli buffer and heated for 5 min at 50 °C. Proteins were
separated  on  an  8%  SDS-polyacrylamide  gel  and
electroblotted to a PVDF membrane (Amersham Biosciences,
Buckinghamshire, UK). Membranes were saturated overnight
at 4 °C with 5% nonfat milk dissolved in TBS-Tween-0.1%,
pH 7.4, which contained 137 mM NaCl, 2.7 mM KCl, 23 mM
Tris, and 0.1% Tween-20. Membranes were then incubated 2
h at room temperature with monoclonal mouse anti-OPA1
antibody  (BD  Bioscience  PharMingen,  Milan,  Italy)  and
mouse  monoclonal  anti-Hsp60  antibody  (Stressgene,
Victoria, Canada). Membranes were then washed three times
in TBS-Tween-0.1% and incubated with 1:10,000 horseradish
peroxidase-conjugated rabbit anti-mouse secondary antibody
for 1 h at room temperature. The immunoreactive proteins
were visualized with enhanced chemiluminescence (ECL Plus
Western  Blotting  Detection  Reagents;  Amersham
Biosciences). Band intensities were quantified with Quantity
One software (Bio-Rad, Hercules, CA).
RESULTS
The clinical examination and MRI confirmed the diagnosis of
isolated bilateral optic neuropathy in our patient. Visual fields
showed large centrocecal defects and central visual field loss.
Visual  evoked  potential  to  a  bright  flash  showed  low-
amplitude  potentials  and  increased  latency  in  both  eyes,
indicating defective conduction of the optic nerves (Figure 2).
Flash-electroretinograms and flicker electroretinograms were
within normal limits (Figure 3). Color-axis confusion lines
were not specific because of many mistakes due to low visual
acuity. MRI of the optic nerve showed severe bilateral atrophy
Figure  2.  Patient  's  visual  evoked
potentials. We observe low-amplitude
potentials  and  increased  latency  in
visual evoked potentials in left eye (A)
and  in  right  eye  (B).  It  indicates
defective conduction of the optic nerves.
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601of the optic nerve from retina to the lateral geniculate nucleus
including atrophy of the optic chiasma and the optic tract
(Figure 4). On T2-weighted and FLAIR acquisitions, no white
matter lesions were found. On orbital high-resolution MRI
with fast spin-echo, there was no obvious change in signal
intensity in the retrobulbar portion of the right optic nerve.
The  analysis  of  the  OPA1  gene  revealed  a  sporadic
heterozygous missense mutation in exon 27: c.2794C>T. This
mutation has not been previously described. The substitution,
which was not found in 400 control chromosomes, is likely to
be causative of disease since it leads to an amino acid change
(p.R932C) in a strongly conserved C-terminal domain of the
OPA1 protein. This domain is predicted to form a coiled-coil
domain, allowing interactions between OPA1 proteins. To
rule out the possibility of an mtDNA variant responsible for
the disease phenotype, we sequenced the patient’s mtDNA,
which revealed an H haplogroup containing 14 nucleotide
differences  relative  to  the  Cambridge  reference  sequence
[27]. No known or potential pathogenic mtDNA variants were
identified. One change at position m.2363A>G in 16S rRNA
has never been seen before in mitochondrial DNA databases.
So far, the large majority of the putative LHON pathogenic
mutations  that  are  associated  with  LHON  are  located  in
complex I subunits. This homoplasmic variant in 16S rRNA
appears very unlikely to be a primary mutation responsible for
the disease phenotype. The identified variants are listed in
Table 2.
Biochemical analysis of the patient’s fibroblasts revealed
mitochondrial  energetic  defects,  thus  confirming  the
pathogenicity of the OPA1 mutation (Table 1). There was a
deficiency in the activity of the terminal enzyme of respiratory
chain,  COX.  The  COX/citrate  synthase  ratio  in  patient’s
fibroblasts was 0.29 versus 0.66±0.12 (n=6) in controls (Table
1). The activity of complexes I, II, III, and V in patient’s
fibroblasts did not differ from that in controls. Mitochondrial
ATP  synthesis  was  greatly  decreased  in  the  patient’s
fibroblasts  compared  to  controls  either  using  malate,
pyruvate, and succinate (maximal coupled respiration state;
Figure  5B)  or  pyruvate  plus  malate  (complex  I  –  related
coupled respiration, not shown). This is probably due to the
reduced  efficiency  of  ATP  synthesis:  the  ATP/O  in  the
patient’s fibroblasts was 1.26 versus 2.37±0.10 in controls
(n=5)  using  malate,  pyruvate,  and  succinate  as  substrates
(Figure 5A), and 1.01 in the patient's cells versus 2.04±0.15
in controls (n=5) using malate and pyruvate (data not shown)
The quantification of mitochondria length distribution
showed  a  larger  proportion  of  short  mitochondria  in  the
patient’s fibroblasts than in controls (Figure 6), as usually
Figure 3. Patient's electroretinograms.
We  show  normal  flicker
electroretinograms  (A),  scotopic
electroretinograms  (B),  and  photopic
electroretinograms (C).
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602observed in fibroblasts from patient with OPA1 mutations.
However, this observation is not correlated to a fragmented
network, which could be shown in apoptotic cells. Culture cell
studies performed on patient’s cells did not show a higher rate
of  apoptosis  nor  a  greater  number  of  necrotic  cells  as
compared to controls. These results were obtained using a
viability test (Trypan blue exclusion test, data not shown).
In  spite  of  the  mutation,  there  was  no  quantitative
modification of OPA1 expression in the patient’s fibroblasts.
We  also  observed  no  alteration  of  the  OPA1  expression
pattern in these cells (Figure 7).
DISCUSSION
ADOA is an inherited optic neuropathy that leads to reduced
visual acuity. It is classically characterized by the insidious
onset of visual impairment in early childhood with moderate
to severe loss of visual acuity, temporal optic disc pallor, color
vision deficits, and centrocecal scotoma of variable density
[28].  Histopathologic  studies  have  shown  that  the
fundamental underlying defect is degeneration of the retinal
ganglion cells, followed by ascending optic atrophy [1]. In
about 70% of the cases, ADOA is due to mutations in the
nuclear OPA1 gene situated on chromosome 3q28-q29 [7,8,
29]. The OPA1 protein is a dynamin-related GTPase targeted
to mitochondria, where it is anchored to the mitochondrial
inner membrane [11,30]. Our analysis of the mitochondrial
network showed that fibroblasts with the c.2794C>T mutation
contained  a  larger  proportion  of  short  mitochondria  than
controls (Figure 6). This finding is in accordance with the
functional  involvement  of  OPA1  in  the  structure  of  the
mitochondrial  network  and  with  the  alterations  of
mitochondrial  structure  observed  in  fibroblasts  carrying
OPA1 mutations [23].
Since the first description of the disease [6], the classic
presentation of ADOA has widened to include less typical
features. Indeed, gender-related variations and intrafamilial
phenotypes heterogeneity of ADOA have been reported [31].
Visual loss has been found to be more severe in affected males
than in females [31]. The expression of the disease is highly
variable,  even  within  a  given  family,  and  asymptomatic
carriers can be found in some families [5,32]. The availability
of molecular testing has revealed phenotypic variations, such
as  severe  congenital  forms  of  optic  atrophy  [16],  ADOA
associated  with  sensorineural  deafness  [18],  and  ADOA
Figure 4. Patient's encephalic MRI. MRI of the optic nerve showed severe bilateral atrophy of the optic nerve from retina to the lateral geniculate
nucleus, seen on horizontal MRI section (A), including atrophy of the optic chiasma, seen on coronal MRI section (B).
TABLE 1. ENZYMATIC ACTIVITIES OF COMPLEXES IV, V AND CITRATE SYNTHASE.
Cells Complex IV Complex V CS Complex IV/CS Complex V/CS
controls 256±40 123±31 362±75 0.68±0.12 0.38±0.11
ADOA 185±44 214±52 363±65 0.51±0.08 0.62±0.15
OPA1_R932C 105 200 368 0.29 0.54
The enzymatic activities were measured in three experiments for the patient and each control subject (n=6). Results are expressed
as mIU (nmol substrate/min/mg protein), and normalized to citrate synthase. Results are given as mean±standard deviation.
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603associated  with  more  complex,  severe  multi-organ
phenotypes [14,15]. However, no correlation has been found
between the degree of visual impairment and the location or
type of mutation in OPA1 [33,34]. The cause of this variable
phenotypic expression remains to be elucidated but could be
due to various genetic or environmental factors. Other genes
encoding  proteins  involved  in  the  modulation  of
mitochondrial bioenergetics and structure may influence the
phenotypic expression of the disease. For instance it has been
shown  that  the  mitochondrial  DNA,  which  encodes
respiratory chain subunits, can influence the expression of
ADOA  [35].  Environmental  factors  such  as  drugs  with
mitochondrial  toxicity  could  also  be  involved  in  the
penetrance and expressivity of the disease.
Our case report demonstrates the existence of a new mode
of onset of ADOA related to OPA1 mutation with an acute
and a late onset that contrast with the earlier and insidious
onset of the disease classically observed and described. The
acute-onset  presentation  of  optic  atrophies  is  usually
associated  with  Leber  hereditary  optic  neuropathy,  which
remains  the  main  differential  diagnosis  of  ADOA.  This
mitochondrial DNA mutation-related disease is classically
associated  with  acute  or  subacute  bilateral  optic  atrophy
occurring  in  the  third  decade  of  life,  and  preferentially
affecting males [36]. Our observation shows that acute-onset
TABLE 2. SEQUENCE VARIATIONS OF THE PATIENT’S MITOCHONDRIAL GENOME.
Nucleotide position Amino acid
substitution
Locus Presence in Mitomap
database
Status
m.263A>G - MT-DLOOP Yes Polymorphism
m.310_311insC - MT-DLOOP Yes Polymorphism
m.750A>G - MT-RNR1 Yes Polymorphism
m.1438A>G - MT-RNR1 Yes Polymorphism
m.2363A>G - MT-RNR2 No Unknown
m.3010G>A - MT-RNR2 Yes Polymorphism
m.4769A>G p.M100M MT-ND2 Yes Synonymous change
m.8860A>G p.T112A MT-ATP6 Yes Polymorphism
m.9966G>A p.V254I MT-CO3 Yes Polymorphism
m.15326A>G p.T194A MT-CYB Yes Polymorphism
m.15742C>A p.L332L MT-CYB No Synonymous change
m.16092T>C - MT-DLOOP Yes Polymorphism
m.16297T>C - MT-DLOOP Yes Polymorphism
m.16519T>C - MT-DLOOP Yes Polymorphism
The patient's mtDNA was entirely sequenced. The sequence was compared to the revised Cambridge reference sequence of
Human  mtDNA. The patient was found to carry 14 nucleotide variations. No known or potential pathogenic mtDNA mutation
were identified.
Figure  5.  Mitochondrial  metabolic
investigations  in  the  patient  and
controls. A: Coupling efficiency (ATP/
O):  Reduced  efficiency  of  ATP
synthesis  was  found  in  the  patient’s
fibroblasts in comparison to controls. B:
Reduced mitochondrial ATP synthesis,
measured by luminescence from aliquot
samples  in  a  polarographic  chamber,
was found in the patient’s fibroblasts in
comparison  to  controls.  C:  Maximal
coupled  respiration  rates,  i.e.,  ADP-
stimulated  oxygen  consumption  with
malate,  pyruvate,  and  succinate,  was
measured  in  the  same  polarographic
chamber.
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604presentations  should  benefit  from  OPA1  analysis  when
LHON mutations have been excluded. Late-onset cases of
optic atrophies are rarely considered to be caused by primary
hereditary  diseases  but  frequently  believed  to  be  due  to
secondary causes. Our case shows that OPA1 analysis can be
useful in late-onset cases of ADOA when the main secondary
causes of optic atrophies have been excluded.
The  novel  OPA1  mutation  is  associated  with  a
mitochondrial energy defect involving reduced ATP synthesis
and a cytochrome c oxidase deficiency. A similar, but less
marked,  biochemical  phenotype  has  been  previously
described in fibroblasts from patients with ADOA carrying
OPA1  mutations;  in  this  study  the  reduced  efficiency  of
oxidative phosphorylation was found to be compensated by a
higher  rate  of  mitochondrial  respiration  to  maintain  ATP
synthesis [22]. In our case, the marked decrease in COX
activity  might  limit  the  possibility  of  compensation  by  a
higher rate of mitochondrial respiration.
In conclusion, we report a novel OPA1 mutation in a
patient with ADOA characterized by sporadic, acute, and late-
Figure  7.  Expression  of  OPA1  protein  in  fibroblasts  from  the
OPA1_R932C  patient  and  from  controls.  Cellular  extracts  were
analyzed by western blotting using antibodies against OPA1 and
HSP60 as described in materials and methods. HSP60 was used as a
mitochondrial marker and as a control for protein loading.
Figure  6.  Quantification  of
mitochondrial  shape  showed  that  the
patient’s  fibroblasts  (OPA1_R932C)
contained a higher proportion of short
mitochondria than controls (Appendix
3).
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605onset presentation. This finding, taken together with several
recently published observations, demonstrates that the clinical
spectrum  of  OPA1-associated  optic  neuropathies  is  much
larger than previously believed. The systematic search for
OPA1 mutations should therefore prove useful in unexplained
and atypical cases of optic atrophy.
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607Appendix 1. Amplification and sequencing primers for OPA1 gene.
The nucleotide sequence of the primers used to amplify
and sequence the 30 OPA1 coding exons, including exon-
intron junctions, is given according to the GenBank reference
sequence NC_000003.10. To access the data, click or select
the words “Appendix 1.” This will initiate the download of a
pdf file that contains the information.
Appendix 2. Amplification and sequencing primers for mtDNA.
The nucleotide sequence of the primers used to amplify
and  sequence  the  entire  mitochondrial  DNA  is  given
according the Revised Cambridge Reference Sequence of the
Human  Mitochondrial  DNA  (RefSeq:  AC_000021.2)
numbering, described as being the “Light strand.” Primers in
Italic were those used for DNA amplification. To access the
data, click or select the words “Appendix 2.” This will initiate
the download of a pdf file that contains the information.
Appendix  3.  Representative  deconvolved  images  used  to  quantify
mitochondrial length:
Mitochondrial length was determined using integrated
morphometric analysis of the Mitotracker®-labeled regions
created after deconvolution. The Figure shows examples of
the  mitochondrial  network  observed  in  the  patient's
fibroblasts.  To  access  the  data,  click  or  select  the  words
“Appendix 3.” This will initiate the download of a pdf file that
contains the information.
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